Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic

Christoph Schulze, Andreas Welker, Anne Kühn, Rainer Schwertz, Benjamin Otto, Laura Moraldo, Udo Dentz, Albertus Arends, Eckhard Welk, Jean-Jacques Wendorff, Hans Koller, Doreen Kuss, Markus Ries, Christoph Schulze, Andreas Welker, Anne Kühn, Rainer Schwertz, Benjamin Otto, Laura Moraldo, Udo Dentz, Albertus Arends, Eckhard Welk, Jean-Jacques Wendorff, Hans Koller, Doreen Kuss, Markus Ries

Abstract

The purpose of this work is to share methods used and lessons learned during a comprehensive inter-institutional pandemic disaster response in Heidelberg, Germany, conveying experiences of the regional SARS-CoV-2 vaccination rollout campaign for up to 1,000,000 vaccines in the year 2020. In this volatile, uncertain, complex, and ambiguous (VUCA) environment, the following five strategic elements were pertinent for institutional arrangements so that specific contributions of the various project partners would be available fast without the necessity of extensive negotiations or information exchange: (1) robust mandate, (2) use of established networks, (3) fast onboarding and securing of commitment of project partners, (4) informed planning of supply capacity, and (5) securing the availability of critical items. Planning tools included analyses through a VUCA lens, analyses of stakeholders and their management, possible failures, and management of main risks including mitigation strategies. The method of the present analysis (VUCA factors combined with analyses of possible failures, and management of stakeholders and risks) can theoretically be adjusted to any public health care emergency anywhere across the globe. Lessons learned include ten tactical leadership priorities and ten major pitfalls.

Keywords: COVID-19; SARS-CoV-2; VUCA world; disaster; disaster management; disaster response; leadership; learning organization; organizational psychology; pandemic; public health; resilience; vaccination; vulnerable populations.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
SARS-CoV-2 vaccination disaster response actors’ diagram. There were four groups of players: (1) the political key stakeholders on different layers (yellow), (2) medical services and organizations (green), (3) public or non-commercial organizations (blue), and (4) private or for-profit organizations (orange). Centralized vaccinations were carried out in Heidelberg, Germany, and the surrounding region, i.e., the Rhine-Neckar district, and parts of the Neckar-Odenwald district and Karlsruhe districts covering a population of 750,000 to 1,000,000 potential vaccine recipients. Vaccine centers were supported by mobile teams in order to better reach vulnerable populations. CIMIC = civil–military cooperation.
Figure 2
Figure 2
(A) (above). Key stakeholder analysis and management. This analysis was conducted on two axes that correspond to power and commitment: “Impact on success” refers to the power of a particular player for the given project, while “supporting change” refers to the institutional will to contribute. The analysis at the beginning of the project was compared to the current situation, with the direction of change in key player management illustrated with arrows. Each player’s position prior to the project was mapped; the arrows show the degree of empowerment and motivation developed over time, mainly through leadership by influence. The vaccine task force set strategic goals; the district coordination team consisted of personnel from a number of offices within the district administration office. The team was made responsible for operational aspects, such as the orders of material and vaccines, as well as the general construction of the vaccination centers and the communication among the different actors. (B) (below). Risk management analysis.

References

    1. Johns Hopkins University COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [(accessed on 14 April 2021)]; Available online: .
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Perez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.
    1. European Medicines Agency EMA Recommends First COVID-19 Vaccine for Authorisation in the EU. [(accessed on 16 April 2021)]; Available online: .
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1.
    1. Sadoff J., Gray G., Vandebosch A., Cardenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. 2021;384:2187–2201. doi: 10.1056/NEJMoa2101544.
    1. Robert Koch Institut Nationale Impfstrategie COVID-19. [(accessed on 16 April 2021)]; Available online: .
    1. Williamsson O.E. The Economic Institutions of Capitalism: Firms, Markets, Relational Contracting. The Free Press; New York, NY, USA: 1985.
    1. Coase R.H. The Nature of the Firm. Economia. 1937;4:386–404.
    1. Williamsson O.E. Transaction Cost Economics: The Natural Progression. Am. Econ. Rev. 2010;100:673–690. doi: 10.1257/aer.100.3.673.
    1. Creswell J.W. Qualitative Inquiry & Research Design: Choosing Among Five Approaches. Sage; Washington, DC, USA: 2012. Narrative Research; pp. 70–76.
    1. Creswell J.W. Qualitative Inquiry & Research Design: Choosing Among Five Approaches. Sage; Washington, DC, USA: 2012. Phenomenological Research; pp. 76–83.
    1. Partners in Health Our approach—PIH’s "Five S’s". [(accessed on 29 July 2021)]; Available online: .
    1. Mink O.G., Esterhuysen P.W., Monk B.P., Owen K.Q. A Comprehensive Management Process. for Transforming Organizations. Jossey-Bass Publishers; San Franscisco, CA, USA: 1993. pp. 440–441.
    1. Baran B.E., Woznyj H.M. Managing VUCA: The human dynamics of agility. Organ. Dyn. 2020;16:100787. doi: 10.1016/j.orgdyn.2020.100787.
    1. Casey G.W., Jr. Leading in a ’VUCA’ world. Fortune. 2014;169:75–76.
    1. Bennett N., Lemoine G.J. What a difference a word makes: Understanding threats to performance in a VUCA world. Bus. Horiz. 2014;57:311–317. doi: 10.1016/j.bushor.2014.01.001.
    1. Nicholson P.J. Health risk from job insecurity needs to be mitigated in these "VUCA times". BMJ. 2013;347:f5504. doi: 10.1136/bmj.f5504.
    1. Till A., Dutta N., McKimm J. Vertical leadership in highly complex and unpredictable health systems. Br. J. Hosp. Med. 2016;77:471–475. doi: 10.12968/hmed.2016.77.8.471.
    1. Alkhaldi K.H., Austin M.L., Cura B.A., Dantzler D., Holland L., Maples D.L., Quarrelles J.C., Weinkle R.K., Jr., Marcus L.J. Are you ready? Crisis leadership in a hyper-VUCA environment. Am. J. Disaster Med. 2017;12:107–134. doi: 10.5055/ajdm.2017.0265.
    1. Maini A., Saravanan Y., Singh T.A., Fyfe M. Coaching skills for medical education in a VUCA world. Med. Teach. 2020;42:1308–1309. doi: 10.1080/0142159X.2020.1788713.
    1. Onaca N., Fleshman J.W. Types of Leadership and How to Use Them in Surgical Areas. Clin. Colon. Rectal. Surg. 2020;33:228–232. doi: 10.1055/s-0040-1709457.
    1. Thomas C. Decision-making during VUCA crises: Insights from the 2017 Northern California firestorm. J. Bus. Contin. Emer. Plan. 2020;14:82–94.
    1. Garcia-Lopez J., Delgadillo J., Vilarrodona A., Querol S., Ovejo J., Coll R., Millan A., Madrigal A., Soria G., Vidal F., et al. SARS-CoV-2/COVID-19 pandemic: First wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. Blood Transfus. 2021;19:158–167. doi: 10.2450/2021.0259-20.
    1. Sturmberg J.P. Without Systems and Complexity Thinking There Is no Progress or Why Bureaucracy Needs to Become Curious Comment on "What Can Policy-Makers Get out of Systems Thinking? Policy Partners’ Experiences of a Systems-Focused Research Collaboration in Preventive Health". Int. J. Health Policy Manag. 2021;10:277–280. doi: 10.34172/ijhpm.2020.45.
    1. Yoder-Wise P.S. From VUCA to VUCA 2.0: Surviving Today to Prosper Tomorrow. Nurs. Educ. Perspect. 2021;42:1–2. doi: 10.1097/01.NEP.0000000000000774.
    1. Ries M., Mechler K., Smith D.L., Herfort B., Visintini J., Santana A.V., Zipf A., Lautenbach S. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope". J. Clin. Pharmacol. 2020;60:826–827. doi: 10.1002/jcph.1643.
    1. Varvasovszky Z., Brugha R. A stakeholder analysis. Health Policy Plan. 2000;15:338–345. doi: 10.1093/heapol/15.3.338.
    1. Donaldson T., Preston L. The stakeholder theory of the corporation: Concepts, evidence, and implications. Acad. Manag. Rev. 1995;20:65–91. doi: 10.5465/amr.1995.9503271992.
    1. Olofsson A., Zinn J.O. Researching Risk and Uncertainty: Methodologies, Methods and Research Strategies. Springer; Berlin/Heidelberg, Germany: 2019.
    1. Ries M., Zielonka M., Ries N., Breil T., Garbade S., Mechler K. Disasters in Germany and France: An Analysis of the Emergency Events Database From a Pediatric Perspective. Disaster Med. Public Health Prep. 2019;13:958–965. doi: 10.1017/dmp.2019.24.
    1. Brennenstuhl H., Will M., Ries E., Mechler K., Garbade S., Ries M. Patterns of extreme temperature-related catastrophic events in Europe including the Russian Federation: A cross-sectional analysis of the Emergency Events Database. BMJ Open. 2021;11:e046359. doi: 10.1136/bmjopen-2020-046359.
    1. Levey J., Levey M. Mindful leadership for personal and organisational resilience. Clin. Radiol. 2019;74:739–745. doi: 10.1016/j.crad.2019.06.026.

Source: PubMed

3
Subscribe